Oncology

Phase 3 trial of cemiplimab monotherapy in advanced cervical cancer stopped early for positive result on overall survival

Regeneron Pharmaceuticals, Inc and Sanofi announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor cemiplimab (Libtayo) monotherapy compared to chemotherapy, in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic. The trial will be stopped early based on...